$29.685
0.615[2.12%]
Last update: 1:54PM Get Real Time Here
Galapagos
(NASDAQ:GLPG)Latest News for Galapagos Stock (NASDAQ:GLPG)
Galapagos Stock (NASDAQ: GLPG)
Categories: All
Monday, April 22, 2024
Thursday, April 04, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Thursday, March 07, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
- Galapagos Expects FY24 Further Reduction In Cash Burn And Expect Cash Burn To Be €280M-€320MBenzinga Newsdesk - Feb 22, 2024, 4:12PM
- Galapgos FY23 EPS €3.21 Up From €(3.32) YoY Revenue €783.5MBenzinga Newsdesk - Feb 22, 2024, 4:08PM
- Earnings Scheduled For February 22, 2024Benzinga Insights - Feb 22, 2024, 5:27AM
Friday, February 16, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
- European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer TreatmentsVandana Singh - Jan 3, 2024, 4:01PM
- BridGene Says "Galapagos Will Pay Up To $27M In Upfront And Preclinical Research Milestone Payments, More Than $700M In Clinical And Commercial Milestones; Eligible To Receive Tiered Royalties On Net Sales Of Each Product Resulting From The Collaboration"Benzinga Newsdesk - Jan 3, 2024, 4:01PM
- BridGene Biosciences Announces Strategic Collaboration With Galapagos To Discover Small Molecule Drugs For Oncology TargetsBenzinga Newsdesk - Jan 3, 2024, 4:00PM
Tuesday, January 02, 2024
Saturday, December 09, 2023
Thursday, November 02, 2023
- Galapagos Reiterates 2023 Net Jyseleca Sales Guidance Of €100M-€120M And Cash Burn Guidance Of €380M-€420MBenzinga Newsdesk - Nov 2, 2023, 4:40PM
- Galapagos 9-Month Total Net Revenues Up 9% To €448.9MBenzinga Newsdesk - Nov 2, 2023, 4:05PM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Thursday, September 21, 2023
Friday, September 15, 2023
Monday, August 28, 2023
- Galapagos Says First patient Randomized In GALACELA, A Phase 2 Systemic Lupus Erythematosus (SLE) Trial With GLPG3667Benzinga Newsdesk - Aug 28, 2023, 4:16PM
- Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667, In Patients With Active Systemic Lupus ErythematosusBenzinga Newsdesk - Aug 28, 2023, 4:01PM
Monday, August 07, 2023
Thursday, August 03, 2023
Tuesday, August 01, 2023
Monday, July 31, 2023
Monday, July 24, 2023
Monday, July 17, 2023
Monday, June 26, 2023
Tuesday, June 20, 2023
Thursday, June 15, 2023
Monday, June 12, 2023
Monday, June 05, 2023
Wednesday, May 31, 2023
Tuesday, May 23, 2023
Tuesday, May 09, 2023
Monday, May 08, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023Benzinga Insights - May 8, 2023, 11:00AM
- RBC Capital Maintains Sector Perform on Galapagos, Lowers Price Target to $41Benzinga Newsdesk - May 8, 2023, 9:24AM
- Raymond James Upgrades Galapagos to Outperform, Announces $69 Price TargetBenzinga Newsdesk - May 8, 2023, 4:26AM